{
    "clinical_study": {
        "@rank": "166611", 
        "acronym": "PNP", 
        "arm_group": {
            "arm_group_label": "The Reprieve system  implantation", 
            "arm_group_type": "Experimental", 
            "description": "The Reprieve implant will be implanted for eligible patients. Implant parameter settings will be set according to patient's sensations."
        }, 
        "brief_summary": {
            "textblock": "The current study will evaluate the safety and performance of the BlueWind Medical Reprieve\n      System for the treatment of  Chronic Painful Peripheral Neuropathy."
        }, 
        "brief_title": "BlueWind Medical Reprieve System for the Treatment of PNP", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Peripheral Neuropathy", 
        "condition_browse": {
            "mesh_term": "Peripheral Nervous System Diseases"
        }, 
        "detailed_description": {
            "textblock": "The BlueWind Reprieve system is a neurostimulator consisting of an Implant and external\n      components.\n\n      The system is intended for home care use. The chronic pain treatment is achieved by an\n      electrical stimulation of peripheral nerve fibers. The stimulation is set so that it\n      generates paresthesia in the stimulated area (e.g. foot), reducing the pain sensation and\n      improving the quality of life for the patient."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Signed written informed consent.\n\n          2. Male or female aged 18 - 80.\n\n          3. Patient agrees to attend all follow-up evaluations and is willing to completely and\n             accurately fill out pain questionnaires.\n\n          4. Diagnosis of chronic neuropathic pain due to peripheral neuropathy.\n\n          5. Documented pain attributed to neuropathy for at least 6 months.\n\n          6. Pain intensity with an average daily VAS score of at least 6, demonstrated by 2-3\n             ratings per day across 7 days.\n\n          7. Patient refractory to conservative treatments including pain medication, for at least\n             6 months.\n\n          8. Stable pain medication for at least 4 weeks prior to study enrollment.\n\n        Exclusion Criteria:\n\n          1. Previous participation in another study with any investigational drug or device\n             within the past 90 days.\n\n          2. Any active implant (cardiac or other).\n\n          3. Any metal implant in the area of BlueWind device implantation site.\n\n          4. Current pregnancy or attempting to get pregnant (female patient).\n\n          5. Any clinically significant neurologic disorders (except PNP).\n\n          6. Any clinically significant or unstable medical or psychiatric condition that would\n             affect the patient's ability to participate in the study.\n\n          7. Patients with severe or unstable cardiovascular, pulmonary, gastrointestinal,\n             hematological, hepatic, renal or endocrine diseases.\n\n          8. Severe peripheral vascular disease that may cause intermittent claudication or\n             ischemic ulcers."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062398", 
            "org_study_id": "CP-02-001"
        }, 
        "intervention": {
            "arm_group_label": "The Reprieve system  implantation", 
            "description": "BlueWind Medical neurostimulator for the treatment of neuropathic pain", 
            "intervention_name": "The Reprieve System", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PNP", 
            "Stimulation", 
            "Peripheral neurostimulation"
        ], 
        "lastchanged_date": "February 13, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sint-Niklaas", 
                        "country": "Belgium", 
                        "zip": "B-9100"
                    }, 
                    "name": "AZ Sint-Niklaas Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland", 
                        "zip": "5 85-981"
                    }, 
                    "name": "10 Military Clinical Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Poland"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Performance of the BlueWind Medical Reprieve System for the Treatment of Patients With Peripheral Neuropathic Pain (PNP)", 
        "overall_contact": {
            "email": "shirley@rainbowmd.com", 
            "last_name": "Shirley Giorini Silfen, PhD", 
            "phone": "+972 9 9531103"
        }, 
        "overall_official": {
            "affiliation": "Sint-Niklaas hospital", 
            "last_name": "Jean Pierre Van Buyten, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: FAGG", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "system and /or procedure related serious adverse events", 
                "measure": "The incidence of serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Pain assessment by Visual Analogue Scale (VAS) as compared to baseline, post activation", 
                "safety_issue": "No", 
                "time_frame": "6 months post system activation"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062398"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measurements include:\nSF-McGill pain Questionnaire Pain related medication consumption/day Quality of life questionnaire SF-36 Health survey and safety", 
            "measure": "Clinical success defined as the effect of the Reprieve System on patient's symptoms", 
            "safety_issue": "No", 
            "time_frame": "6 months post system activation"
        }, 
        "source": "Rainbow Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Rainbow Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}